152 related articles for article (PubMed ID: 9869797)
1. Exposure to allopurinol and the risk of cataract extraction in elderly patients.
Garbe E; Suissa S; LeLorier J
Arch Ophthalmol; 1998 Dec; 116(12):1652-6. PubMed ID: 9869797
[TBL] [Abstract][Full Text] [Related]
2. Association of inhaled corticosteroid use with cataract extraction in elderly patients.
Garbe E; Suissa S; LeLorier J
JAMA; 1998 Aug; 280(6):539-43. PubMed ID: 9707144
[TBL] [Abstract][Full Text] [Related]
3. Association of gout medications and risk of cataract: a population-based case-control study.
Li YJ; Perng WT; Tseng KY; Wang YH; Wei JC
QJM; 2019 Nov; 112(11):841-846. PubMed ID: 31286139
[TBL] [Abstract][Full Text] [Related]
4. Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol.
Paisansinsup T; Breitenstein MK; Schousboe JT
J Clin Rheumatol; 2013 Jun; 19(4):180-6. PubMed ID: 23669799
[TBL] [Abstract][Full Text] [Related]
5. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
[TBL] [Abstract][Full Text] [Related]
6. Allopurinol and the incidence of bladder cancer: a Taiwan national retrospective cohort study.
Chen CJ; Hsieh MC; Liao WT; Chan YT; Chang SJ
Eur J Cancer Prev; 2016 May; 25(3):216-23. PubMed ID: 25830898
[TBL] [Abstract][Full Text] [Related]
7. Selective Serotonin Reuptake Inhibitors and Cataract Risk: A Case-Control Analysis.
Becker C; Jick SS; Meier CR
Ophthalmology; 2017 Nov; 124(11):1635-1639. PubMed ID: 28571893
[TBL] [Abstract][Full Text] [Related]
8. Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study.
Søltoft Larsen K; Pottegård A; Lindegaard HM; Hallas J
PLoS One; 2016; 11(1):e0146172. PubMed ID: 26751377
[TBL] [Abstract][Full Text] [Related]
9. Allopurinol use and the risk of cataract formation.
Clair WK; Chylack LT; Cook EF; Goldman L
Br J Ophthalmol; 1989 Mar; 73(3):173-6. PubMed ID: 2706206
[TBL] [Abstract][Full Text] [Related]
10. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
Stamp LK; Taylor WJ; Jones PB; Dockerty JL; Drake J; Frampton C; Dalbeth N
Arthritis Rheum; 2012 Aug; 64(8):2529-36. PubMed ID: 22488501
[TBL] [Abstract][Full Text] [Related]
11. Cataracts associated with allopurinol therapy.
Fraunfelder FT; Hanna C; Dreis MW; Cosgrove KW
Am J Ophthalmol; 1982 Aug; 94(2):137-40. PubMed ID: 7114136
[TBL] [Abstract][Full Text] [Related]
12. Clinical risk factors for adverse events in allopurinol users.
Ryu HJ; Song R; Kim HW; Kim JH; Lee EY; Lee YJ; Song YW; Lee EB
J Clin Pharmacol; 2013 Feb; 53(2):211-6. PubMed ID: 23436266
[TBL] [Abstract][Full Text] [Related]
13. Allopurinol and cataracts.
Jick H; Brandt DE
Am J Ophthalmol; 1984 Sep; 98(3):355-8. PubMed ID: 6476060
[TBL] [Abstract][Full Text] [Related]
14. Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure.
Singh JA; Yu S
Ann Rheum Dis; 2017 Jan; 76(1):133-139. PubMed ID: 27296322
[TBL] [Abstract][Full Text] [Related]
15. The prevalence and morphology of cataract in patients on allopurinol treatment.
Liu CS; Brown NA; Leonard TJ; Bull PW; Scott JT
Eye (Lond); 1988; 2 ( Pt 6)():600-6. PubMed ID: 3256496
[TBL] [Abstract][Full Text] [Related]
16. Gout, allopurinol use, and heart failure outcomes.
Thanassoulis G; Brophy JM; Richard H; Pilote L
Arch Intern Med; 2010 Aug; 170(15):1358-64. PubMed ID: 20696962
[TBL] [Abstract][Full Text] [Related]
17. Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.
Coburn BW; Bendlin KA; Sayles H; Meza J; Russell CL; Mikuls TR
J Clin Rheumatol; 2017 Sep; 23(6):317-323. PubMed ID: 28816767
[TBL] [Abstract][Full Text] [Related]
18. Lifetime exposure to ambient ultraviolet radiation and the risk for cataract extraction and age-related macular degeneration: the Alienor Study.
Delcourt C; Cougnard-Grégoire A; Boniol M; Carrière I; Doré JF; Delyfer MN; Rougier MB; Le Goff M; Dartigues JF; Barberger-Gateau P; Korobelnik JF
Invest Ophthalmol Vis Sci; 2014 Oct; 55(11):7619-27. PubMed ID: 25335979
[TBL] [Abstract][Full Text] [Related]
19. Further studies on allopurinol therapy and human cataractogenesis.
Lerman S; Megaw J; Fraunfelder FT
Am J Ophthalmol; 1984 Feb; 97(2):205-9. PubMed ID: 6696031
[TBL] [Abstract][Full Text] [Related]
20. Allopurinol--dose according to effect, not renal function.
Bryant L
J Prim Health Care; 2011 Dec; 3(4):323. PubMed ID: 22235497
[No Abstract] [Full Text] [Related]
[Next] [New Search]
